The global market for diagnostic biomarkers detecting cardiovascular disease is expected to soar steadily at a compound annual growth rate of 12.8 percent between 2013 and 2018.

A partnership between the Broad Institute’s Stanley Center for Psychiatric Research in Cambridge, Mass., and Tetra Discovery Partners based in Grand Rapids, Mich., that pores over the human genome for specific variants in schizophrenia may make way for new pharmaceutical therapies for psychiatric disease, Tetra announced April 9.

A prospective Parkinson’s imaging agent taps into alpha-synuclein deposition in the brain, developers ICB International announced April 11.

Runaway production of proteins tripped off by a genetic mutation may be the culprit in the neurological damage associated with Parkinson’s disease, the National Institutes of Health announced yesterday.

A novel theranostics technique uses dual infrared photon laser beams to release chemotherapy within tumor cells for next-generation imaging biomarker and targeted therapy, according to an announcement from the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles.

A small group of proteins called transcription factors that regulate genetic expression tip off the mother cells of very aggressive and therapy-resistant brain cancer, according to Massachusetts General Hospital research announced by the institution yesterday.

SBRI contract to explore potential of low-cost commercial 3D scanner in healthcare applicationsOxford, UK & Greenville, NC – April 9, 2014 – Fuel 3D Technologies Ltd., developer of 3D scanning solutions, today announced it has secured a £685,831 ($1.1 million) SBRI Healthcare development contract for the development of a 3D medical imaging system. SBRI Healthcare is an NHS England initiative, which aims to promote UK economic growth while addressing unmet health needs and enhancing the take up of known best practice. Fuel 3D Technologies will use the contract to develop its Eykona scanner technology for a range of therapy applications and adoption in the NHS and international healthcare markets.

An international consortium has been awarded a $1.8 million grant from the European Commission to assess Cerenkov luminescence imaging for intraoperative imaging of gastric cancer patients.